Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

NovoEight

- PMLiVE

FDA panel votes against Actavis hypertension combo

Places a question mark over the combination of Bystolic and Diovan

- PMLiVE

Liraglutide seems effective in obesity, says FDA reviewer

Novo Nordisk drug is already successful diabetes treatment

- PMLiVE

Merck brings first PD-1 inhibitor to US market

FDA approves Keytruda for advanced melanoma

- PMLiVE

Drug regulators collaborate to tackle Ebola outbreak

EMA and FDA team up with global partners to accelerate access to medicines

- PMLiVE

Novo Nordisk gives up on inflammation R&D

Follows disappointing trial results for arthritis drug

- PMLiVE

Novo Nordisk debuts diabetes combo in Mexico

Requires fewer daily injections than current insulin treatment

- PMLiVE

UCB wins new epilepsy indication for Vimpat in the US

FDA approves drug as monotherapy in patients with partial-onset seizures

- PMLiVE

Team Novo Nordisk to compete in The Tour of Britain

World’s first all-diabetes pro-cycling team will cycle over 1,300km in eight days

- PMLiVE

Amgen claims first-to-file spot in PCSK9 inhibitor race

Evolocumab is part of new class of treatment to tackle high cholesterol

- PMLiVE

Rapid review for Pfizer’s superbug vaccine

FDA to expedite assessment of Clostridium difficile inoculation

- PMLiVE

Amgen gets priority review for chronic heart failure hope

Raises expectations for early entry onto US market for ivabradine

- PMLiVE

Novo launches diabetes campaign in Copenhagen

Follows introduction of ‘Cities Changing Diabetes’ programme in Mexico

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links